CytoSolve® Has ONLY Raised $1 Million Proving Its Revolutionary Approach Works, While Other Companies Have Scammed Investors
Faster. Cheaper. Safer.
CytoSolve®, since its founding in 2012, CytoSolve® has raised only $1 million through angel financing. Other companies in the Biotech, AI, Systems Biology space have raised tens of millions to billions of dollars, scamming investors and delivering either bankrupt companies or failed therapeutics. Look at our Research Pipeline, Publications, Patents, Products, and Services below. We are now poised for explosive growth and are now seeking strategic partners. Email us at info@cytosolve.com to learn more.
A Revolutionary New Paradigm for Discovery & Development
Dr. Shiva Ayyadurai, MIT PhD, the Man Who Invented Email, is now Revolutionizing Health with his creation of CytoSolve®, a pioneering technology platform for computational systems biology that goes beyond AI to deliver a scientifically validated, scalable, and repeatable framework that provides a systems-level understanding of disease and complex biological systems, in silico, thereby reducing and even eliminating the need for animal testing, to discover multi-combination therapies that address the root cause of biological dysfunction.
CytoSolve’s Six-Phased Systems Biology Research Paradigm delivers discovery, development, and validation that are faster, cheaper, and safer than existing traditional reductionist approaches. Using this paradigm, CytoSolve® has engineered multi-ingredient drug and nutraceutical combinations in silico that have been cleared by the U.S. Food and Drug Administration (FDA) to advance to human clinical trials—without the need for animal testing.
Research Pipeline
CytoSolve®’s research ecosystem spans diverse research areas including oncology, neurodegeneration, cardiovascular health, immunology, metabolic disorders, and host–microbiome interactions, among others.
Each project follows a rigorous scientific workflow: mining thousands of peer-reviewed papers, constructing detailed molecular systems architectures, developing mathematically calibrated models, and simulating therapeutic interventions in silico. This methodology uncovers synergistic interactions, identifies new molecular targets, and reveals therapeutic insights inaccessible to reductionist research.
Publications
CytoSolve’s research is published in world-class peer-reviewed journals such as Nature, Cell, IEEE, etc. Our research is motivated by principles of Systems Science, far different than the reductionist approach.
Stem Cells2025
NATURE Systems Biology and Applications2025
Nutrients2023
Journal of American Dental Association2023
Nutrients2023
Applied sciences2022
European Society for Clinical Nutrition & Metabolism 2022
Cancers2022
Clinical Nutrition ESPEN2021
Journal of Dietary Supplements2021
American Journal of Plant Sciences2016
NATURE Neuroscience2016
Agricultural Sciences2015
American Journal of Plant Sciences2015
American Journal of Plant Sciences2015
Agricultural Sciences2015
CELL's Biophysical Journal2013
BMC BioInformatics2012
IEEE Transactions On Biomedical Engineering2011
Communications in Medical and Care Compunetics2010
Cellular and Molecular Bioengineering2010
Patents
CytoSolve® holds a growing portfolio of patents that capture innovations in systems-level computational biology and multi-ingredient therapeutic composition design.
Improving Joint Health2023
Antioxidant2024
Improving Low Testosterone Levels2023
The patents span breakthrough compositions for cognitive health, antioxidants, metabolic support, hormonal balance, and other physiologic enhancements. Additional patents protect CytoSolve®’s core technology: a distributed, service-oriented architecture for integrating molecular pathway models that powers its whole-cell simulation engine. This intellectual property foundation reflects CytoSolve®’s long-term commitment to translating molecular systems science into novel, clinically relevant solutions.
Products
CytoSolve® OPTIMIZED™ products are a new category of scientifically engineered formulations developed through rigorous in silico modeling, not marketing hype.
Each product is designed by simulating thousands of molecular interactions across relevant pathways to identify the safest and most effective synergistic combinations. This precision-based approach ensures that every formulation operates on multiple molecular targets simultaneously. CytoSolve®’s supplements, herbal teas, and canine vitality products represent the future of evidence-based wellness solutions.
Upcoming CytoSolve® Symposium
23rd Century Platform
COMPUTATIONAL BIOLOGY
CytoSolve® is pioneering the future of biomedical innovation with a revolutionary “23rd Century Platform” for discovering, developing, and delivering therapeutics—without animal testing, guesswork, or pharmaceutical trial-and-error.
CytoSolve’s cloud-based computational engine integrates entire molecular pathway networks in silico, enabling scientists to simulate complex biological systems with unprecedented accuracy. By linking independently developed models into one dynamic architecture, CytoSolve® reveals emergent behaviors across whole-cell systems, transforming how medicines, nutrients, and botanical formulations are designed. This platform sets a new global standard for scientific transparency, speed, and predictive power.
Personalized Health
DIGITAL TWINS
CytoSolve® makes personalized health a measurable, science-based reality. By modeling how specific nutrients, botanicals, and compounds interact with molecular pathways unique to an individual’s condition, CytoSolve® moves beyond generic health advice to deliver targeted, constitution-specific guidance.
CytoSolve’s systems biology engine analyzes large-scale molecular data to reveal how interventions modulate inflammation, immunity, metabolism, and oxidative stress in different people. This approach supports tailored nutraceuticals, customized protocols, and individualized wellness strategies based on a person’s actual molecular system—not one-size-fits-all assumptions.
Precision Medicine
DIGITAL FORMULATION
CytoSolve® advances precision medicine by simulating therapeutic effects at the system-wide molecular level rather than relying on isolated, single-target analysis.
CytoSolve’s computational modeling integrates pathways related to inflammation, oxidative stress, immune cascades, metabolic regulation, and cancer microenvironments—allowing researchers to visualize exactly how combinations of ingredients or drug candidates influence entire biological networks. This enables prediction of dose-response relationships, identification of synergistic effects, and optimization of therapies before laboratory or clinical testing. CytoSolve® brings true precision—multi-target, multi-pathway, fully modeled—to therapeutic design.
Integrating World-Class Discoveries
Developing and Validating Large-Scale Systems Architectures and In-Silico Models of Diseases and Complex Biological Phenomena
Institutions
0
Scientists
0
Experiments
0
HISTORY OF CYTOSOLVE®
CytoSolve® was founded by Dr. Shiva Ayyadurai in 2012. Below is the video of the State of the Art Lecture at the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Dr. Shiva was honored by ASCPT for his invention of CytoSolve® that gives a detailed background on CytoSolve®.
Events and Education
MOLECULAR SYSTEMS
CytoSolve® is committed to democratizing scientific knowledge through its molecular systems public education mission.
CytoSolve® translates complex molecular interactions into clear, actionable insights for everyday people. Through platforms like CytoSolve® Symposiums, The Open Science Institute™, and video lecture on Social Media, the public gains access to unbiased, data-driven explanations of how foods, herbs, diseases, and nutrients work at the molecular level. This initiative breaks down the barriers of Big Pharma and Big Academia, empowering individuals with real scientific literacy.
COLLABORATIONS
OUR CHAIRMAN & CEO
Dr. Shiva Ayyadurai, the Founder and CEO of CytoSolve®, Inc., is the Inventor of Email and holds 4 degrees from MIT. He is a Fulbright Scholar and has started 7 successful hi-tech companies including EchoMail, CytoSolve® and Systems Health®. He is also the Founder of Center for Integrative Systems that performs fundamental research in systems thinking and is the home of Innovation Corps™ and C.L.E.A.N./R.A.W.® certifications. He is now a candidate for US Senate from Massachusetts.